Analyst Ratings For CRH Medical Corp (TSE:CRH)
Today, CRH Medical Corp (TSE:CRH) stock was downgraded by Bloom Burton from Buy to Accumulate.
There are 4 hold ratings, 4 buy ratings on the stock.
The current consensus rating on CRH Medical Corp (TSE:CRH) is Buy (Score: 2.50) with a consensus target price of C$9.45 per share, a potential .
Some recent analyst ratings include
- 2/24/2017-Bloom Burton was Downgraded by analysts at Bloom Burton from a “Buy ” rating to a ” Accumulate” rating.
- 2/24/2017-Beacon Securities Reiterated Rating of Buy.
- 2/24/2017-TD Securities Reiterated Rating of Buy.
- 2/23/2017-Royal Bank of Canada Reiterated Rating of Sector Perform.
- 2/15/2017-National Bank Financial Reiterated Rating of Sector Perform.
About CRH Medical Corp (TSE:CRH)
CRH Medical Corporation, formerly Medsurge Medical Products Corp., is a healthcare products and services company. The Company operates through segments, including the sale of medical products and the provision of anesthesia services. The Company specializes in the treatment of hemorrhoids utilizing its treatment protocol and technology. The Company also provides anesthesiology services to gastroenterologists in the southeastern United States through its subsidiaries. The Company’s product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company’s first product, the CRH O’Regan System, is a single use, disposable, hemorrhoid banding technology for treating hemorrhoid grades I – IV. It principally operates in the United States. It distributes the CRH O’Regan System to physicians. The Company’s subsidiary, Gastroenterology Anesthesia Associates, LLC, provides anesthesiology services for gastroenterology procedures.
Recent Trading Activity for CRH Medical Corp (TSE:CRH)
Shares of CRH Medical Corp closed the previous trading session at 9.27 up +0.21 2.32% with 708,786 shares trading hands.
